Toxys Awarded Phase 1 Project in CRACK IT Challenge

CRACK IT is a challenge-led competition that funds collaborations between industry, academics and SMEs to solve business and scientific Challenges which will deliver 3Rs benefits, either by improving business processes or developing a commercial product. Depending on the Challenge, contracts of up to £1M for up to three years are available. 

Toxys receives Phase 1 CrossDART Challenge Award 

The award is sponsored by AbbVie, AstraZeneca, Bayer AG, Boehringer Ingelheim, LEO Pharma A/S, Merck Healthcare KGaA, MMV Medicines for Malaria Venture, Novartis and Roche, with the aim to develop and integrate in vitro approaches that can reliably predict early or surrogate indicators of teratogenicity of pharmaceutical drug candidates. 

The project from Toxys, lead by our CSO Dr Amer Jamalpoor, is one of the first two projects to receive a Phase 1 award. During the proof-of-concept phase, our team will establish and characterize in vitro assays in human and one preclinical species. Once complete, awardees can apply for up to £1M over three years to deliver the full Challenge requirements.

“At Toxys, our mission is centered on leveraging scientific innovation and pioneering new approach methodologies to contribute to the development of safer medicines and products, without the need for animal experimentation.” 

Dr Amer Jamalpoor, CSO Toxys 

You can learn more about the challenge here: 

CRACK IT – https://nc3rs.org.uk/crackit/crack-it-challenges 

CrossDART – https://nc3rs.org.uk/crackit/crossdart 

Award news on NC3Rs website – https://www.nc3rs.org.uk/crackit/news/ps600k-awarded-proof-concept-studies-advance-development-new-approach-methodologies